CINCINNATI, July 29 /PRNewswire/ -- Medpace, a leading global full-service contract research organization, announced it has hired Yong-Xi Li as Executive Director of the new Medpace Bioanalytical Laboratories.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080729/CLTU002LOGO )
Dr. Li joins Medpace with a strong background in bioanalytical technology, method development, validation, and sample analysis in support of pharmaceutical development and both preclinical and clinical studies. At Medpace, Dr. Li will direct operations and activities of the new, advanced Mass Spectrometry Medpace Bioanalytical Laboratories, including bioanalytical aspects for small and large drug molecules according to GLP and GMP compliances and ICH guidelines. This new laboratory is projected to open in fall of 2008 and will complement services provided by other Medpace research facilities, such as Medpace Clinical Pharmacology and Medpace Reference Laboratories.
Dr. Li comes to Medpace from Eurofins Scientific, NJ, where he served as Senior Director, managing their laboratory process and facilitating bioanalytical technology and methods. Prior to his work at Eurofins Scientific, Dr. Li was the Vice President of Ricerca LLC and then the Vice President of XenoBiotics Laboratories, Inc., where he led and expanded the bioanalytical laboratories and activities.
Dr. Li arrived in the US and worked as a senior research scientist under Dr. K.J. Klubende and Dr. B.H. Davis to establish his first bioanalytical laboratory. He went on to do postdoctoral studies in Chemistry at Cornell University, Baker Laboratory, in Ithaca, New York, under Professor Emeritus S.H. Bauer. Dr. Li has authored numerous scientific and clinical publications in the fields of proteomics and quantitation analysis.
"We are excited to have an experienced chemist such as Yong-Xi Li on staff," said August Troendle, MD, Medpace Chief Executive Officer. "Yong-Xi's bioanalytical expertise is a good fit for our company as we continue to expand our laboratory capabilities."
ABOUT MEDPACE
Medpace is a leading global full-service contract research organization led by top therapeutic and regulatory experts who are driven to further the advancement of pharmaceutical agents for use in cardiology, metabolism, and oncology. Medpace has assembled the industry's most experienced and therapeutically focused team to execute at every level of the company's operations, providing complete and seamless drug development services.
Through specialized regulatory expertise and therapeutically focused clinical operations, Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development -- from program planning and execution to product approval.
With more than 700 employees and clinical trial experience in over 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide within the core therapeutic areas of cardiology, metabolism, and oncology.
Medpace provides centralized image management and reading from Imagepace, centralized laboratory and therapeutically specialized testing from Medpace Reference Laboratories, and Phase I / IIa research services from Medpace Clinical Pharmacology.
CONTACT: John Wynne of Medpace, +1-513-579-9911, ext. 2407,
j.wynne@medpace.com
Web site: http://www.medpace.com/